THE BioMed Co., Ltd. (KOSDAQ:214610)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,300.00
+10.00 (0.23%)
At close: Oct 2, 2025
0.23%
Market Cap33.25B
Revenue (ttm)1.71B
Net Income (ttm)-24.69B
Shares Out8.38M
EPS (ttm)-5,190.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,950
Average Volume16,342
Open4,290.00
Previous Close4,290.00
Day's Range4,120.00 - 4,395.00
52-Week Range4,050.00 - 21,800.00
Beta0.22
RSI34.88
Earnings DateNov 14, 2025

About THE BioMed

THE BioMed Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides bio... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2009
Employees 48
Stock Exchange KOSDAQ
Ticker Symbol 214610
Full Company Profile

Financial Performance

In 2024, THE BioMed's revenue was 4.64 billion, a decrease of -13.55% compared to the previous year's 5.37 billion. Losses were -30.85 billion, 19.7% more than in 2023.

Financial Statements

News

There is no news available yet.